Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free GOCO Stock Alerts

GoHealth (GOCO) Financials

GoHealth logo
$0.30 -0.01 (-2.30%)
Closing price 06/15/2026
Extended Trading
$0.30 0.00 (0.00%)
As of 06/15/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for GoHealth

Annual Income Statements for GoHealth

This table shows GoHealth's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 28 -44 -189 -149 -63 -2.93 -257
Consolidated Net Income / (Loss)		 28 -97 -534 -376 -151 -7.32 -498
Net Income / (Loss) Continuing Operations		 28 -97 -534 -376 -151 -7.32 -497
Total Pre-Tax Income 		28 -97 -534 -376 -151 -5.05 -501
Total Revenue		 -0.22 -33 1,017 575 -69 873 -89
Net Interest Income / (Expense)		 -0.22 -33 -34 -57 -69 0.00 -87
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.22 33 34 57 69 0.00 87
Long-Term Debt Interest Expense		 0.22 33 34 57 69 - 87
Total Non-Interest Income		 0.00 0.00 1,050 632 0.00 873 -1.66
Net Realized & Unrealized Capital Gains on Investments		 - 0.00 -12 0.00 0.00 74 -1.66
Total Non-Interest Expense		 -29 65 1,552 950 82 879 413
Net Occupancy & Equipment Expense		 16 59 48 46 43 41 35
Marketing Expense		 28 207 365 208 205 236 116
Other Operating Expenses		 153 562 657 565 461 508 293
Amortization Expense		 0.00 94 94 94 94 94 71
Impairment Charge		 - 0.00 388 25 13 0.00 260
Other Special Charges		 -226 -877 - - -735 - -362
Income Tax Expense		 0.05 0.04 -0.02 0.76 0.15 2.27 -3.34
Other Gains / (Losses), net		 - - - - 0.04 - 0.79
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.00 -53 -345 -228 -88 -4.39 -241
Basic Earnings per Share		 $0.00 ($3.35) ($26.80) ($17.72) ($7.19) ($0.66) ($20.17)
Weighted Average Basic Shares Outstanding		 0.00 5.61M 7.07M 8.45M 9.29M 9.98M 12.94M
Diluted Earnings per Share		 $0.00 ($3.35) ($26.80) ($17.72) ($7.19) ($0.66) ($20.17)
Weighted Average Diluted Shares Outstanding		 0.00 5.61M 7.07M 8.45M 9.29M 9.98M 12.94M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 84.19M 321.28M 22.04M 22.48M 23.01M 28.85M

Quarterly Income Statements for GoHealth

This table shows GoHealth's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -24 -1.23 -9.22 -26 6.78 26 -4.41 -54 -166 -33 -37
Consolidated Net Income / (Loss)		 -56 -2.29 -21 -59 15 58 -9.79 -116 -314 -58 -66
Net Income / (Loss) Continuing Operations		 -56 -2.29 -21 -59 15 58 -9.79 -116 -314 -57 -66
Total Pre-Tax Income 		-56 -1.92 -21 -59 15 60 -8.68 -116 -314 -62 -65
Total Revenue		 132 -167 168 88 177 349 205 -17 -26 -251 -19
Net Interest Income / (Expense)		 0.00 -35 -18 -18 -19 -37 -16 -17 -25 -30 -31
Total Interest Income		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Interest Expense		 0.00 35 18 18 19 37 16 17 25 30 31
Long-Term Debt Interest Expense		 - - 18 18 19 - 16 17 25 30 31
Total Non-Interest Income		 132 -132 186 106 196 386 221 0.00 -1.66 -221 12
Other Non-Interest Income		 132 - 186 106 118 389 221 - - - 12
Total Non-Interest Expense		 188 -165 190 146 161 290 214 99 288 -189 47
Net Occupancy & Equipment Expense		 12 12 11 8.57 9.80 12 9.04 8.21 9.97 7.68 7.66
Marketing Expense		 39 81 53 38 45 100 67 28 17 3.44 2.22
Other Operating Expenses		 113 118 103 76 82 154 114 81 65 34 37
Amortization Expense		 24 24 24 24 24 24 24 24 24 - 0.00
Impairment Charge		 0.00 - 0.00 0.00 - - 0.71 53 206 - 0.00
Nonoperating Income / (Expense), net		 -0.77 - 0.57 -0.65 -0.25 1.17 0.60 - - - 0.16
Income Tax Expense		 -0.11 0.38 -0.07 -0.04 -0.01 2.39 1.10 -0.35 -0.49 -3.60 0.71
Net Income / (Loss) Attributable to Noncontrolling Interest		 -32 -1.07 -12 -33 8.59 32 -5.38 -62 -148 -25 -29
Basic Earnings per Share		 ($2.61) ($0.13) ($1.04) ($2.70) $0.58 $2.56 ($0.52) ($5.10) ($11.80) ($2.75) ($2.36)
Weighted Average Basic Shares Outstanding		 9.49M 9.29M 9.72M 9.97M 10.08M 9.98M 10.37M 10.83M 14.14M 12.94M 16.20M
Diluted Earnings per Share		 ($2.61) ($0.13) ($1.04) ($2.70) $0.46 $2.56 ($0.52) ($5.10) ($11.80) ($2.75) ($2.36)
Weighted Average Diluted Shares Outstanding		 9.49M 9.29M 9.72M 9.97M 14.58M 9.98M 10.37M 10.83M 14.14M 12.94M 16.20M
Weighted Average Basic & Diluted Shares Outstanding		 22.37M 22.48M 22.73M 22.84M 22.91M 23.01M 23.74M 28.61M 28.71M 28.85M 29.30M

Annual Cash Flow Statements for GoHealth

This table details how cash moves in and out of GoHealth's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.67 132 -60 -68 74 -50 -8.02
Net Cash From Operating Activities		 5.44 -114 -299 61 109 -22 -122
Net Cash From Continuing Operating Activities		 5.44 -114 -299 61 109 -22 -122
Net Income / (Loss) Continuing Operations		 28 -97 -534 -376 -151 -7.32 -498
Consolidated Net Income / (Loss)		 28 -97 -534 -376 -151 -7.32 -498
Depreciation Expense		 6.16 4.50 13 13 12 12 9.56
Amortization Expense		 0.00 96 96 97 97 103 78
Non-Cash Adjustments to Reconcile Net Income		 0.79 234 432 57 35 -59 313
Changes in Operating Assets and Liabilities, net		 -30 -352 -306 270 116 -70 -25
Net Cash From Investing Activities		 -6.17 -15 -20 -14 -14 3.81 -8.25
Net Cash From Continuing Investing Activities		 -6.17 -15 -20 -14 -14 3.81 -8.25
Purchase of Investment Securities		 -6.17 -15 -20 -14 -14 -14 -8.25
Divestitures		 - - - 0.00 0.00 18 0.00
Net Cash From Financing Activities		 0.06 261 259 -115 -21 -32 122
Net Cash From Continuing Financing Activities		 0.06 261 259 -115 -21 -32 122
Issuance of Debt		 83 117 565 0.00 0.00 558 138
Repayment of Debt		 -82 -10 -309 -163 -15 -589 -11
Payment of Dividends		 - - 0.00 0.00 -3.57 0.00 0.00
Other Financing Activities, Net		 -0.08 -608 3.40 -1.98 -2.20 -1.11 -5.22
Effect of Exchange Rate Changes		 -0.00 0.04 -0.16 -0.24 0.04 -0.06 0.18
Cash Interest Paid		 0.22 33 28 57 55 66 46
Cash Income Taxes Paid		 0.03 0.29 0.88 0.49 0.55 0.42 0.43

Quarterly Cash Flow Statements for GoHealth

This table details how cash moves in and out of GoHealth's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 1.02 64 7.01 -84 21 5.39 -19 13 -3.51 0.83 6.98
Net Cash From Operating Activities		 6.50 71 13 -36 -12 15 -12 -38 -33 -39 6.99
Net Cash From Continuing Operating Activities		 6.50 71 13 -36 -12 15 -12 -38 -33 -39 6.99
Net Income / (Loss) Continuing Operations		 -56 -2.29 -21 -59 15 58 -9.79 -116 -314 -58 -66
Consolidated Net Income / (Loss)		 -56 -2.29 -21 -59 15 58 -9.79 -116 -314 -58 -66
Depreciation Expense		 2.75 3.33 2.73 2.78 2.91 3.41 2.96 2.68 3.51 0.41 0.31
Amortization Expense		 24 24 25 27 27 25 25 25 26 2.89 3.05
Non-Cash Adjustments to Reconcile Net Income		 2.75 15 2.70 2.88 -74 9.31 4.27 67 226 16 16
Changes in Operating Assets and Liabilities, net		 33 31 3.65 -9.38 17 -81 -34 -16 26 0.16 54
Net Cash From Investing Activities		 -3.43 -5.65 -4.56 -2.70 13 -2.22 -3.05 -2.83 -2.37 - 0.00
Net Cash From Continuing Investing Activities		 -3.43 -5.65 -4.56 -2.70 13 -2.22 -3.05 -2.83 -2.37 - 0.00
Purchase of Investment Securities		 -3.43 -5.65 -4.56 -2.70 -4.25 -2.22 -3.05 -2.83 -2.37 - 0.00
Net Cash From Financing Activities		 -2.19 -1.09 -0.94 -44 20 -6.97 -3.20 54 31 40 -0.03
Net Cash From Continuing Financing Activities		 -2.19 -1.09 -0.94 -44 20 -6.97 -3.20 54 31 40 -0.03
Repayment of Debt		 0.07 - 0.00 -59 -4.53 -526 -2.38 -0.43 -7.98 - 0.00
Other Financing Activities, Net		 -1.37 -0.20 -0.94 -0.39 -0.15 0.37 -0.82 -4.21 -0.10 -0.09 -0.03
Effect of Exchange Rate Changes		 0.14 -0.15 -0.01 -0.05 0.02 -0.02 -0.12 0.22 0.09 -0.01 0.01

Annual Balance Sheets for GoHealth

This table presents GoHealth's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1,602 2,109 2,069 1,659 1,500 1,488 987
Cash and Due from Banks		 12 144 84 16 91 41 33
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible Assets		 783 689 595 501 397 302 5.15
Other Assets		 414 869 1,366 1,117 985 1,116 949
Total Liabilities & Shareholders' Equity		 1,602 2,109 2,069 1,659 1,500 1,488 987
Total Liabilities		 742 710 1,176 1,068 1,045 1,030 993
Short-Term Debt		 17 13 51 29 99 60 78
Accrued Interest Payable		 79 105 157 175 214 220 35
Other Short-Term Payables		 18 9.06 8.88 61 58 58 29
Long-Term Debt		 288 396 665 505 423 448 637
Other Long-Term Liabilities		 341 186 294 297 252 244 214
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - 0.00 49 49 53 57
Total Equity & Noncontrolling Interests		 860 1,399 892 542 406 405 -62
Total Preferred & Common Equity		 0.00 380 353 269 231 242 38
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 860 380 353 269 231 242 38
Common Stock		 0.00 399 561 626 654 669 728
Retained Earnings		 0.00 -19 -208 -357 -420 -423 -680
Treasury Stock		 - - 0.00 -0.35 -2.64 -4.15 -9.37
Accumulated Other Comprehensive Income / (Loss)		 -0.02 0.02 -0.06 -0.14 -0.13 -0.15 -0.06
Noncontrolling Interest		 0.00 1,019 539 274 175 164 -100

Quarterly Balance Sheets for GoHealth

This table presents GoHealth's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,437 1,395 1,257 1,341 1,382 1,311 1,030 918
Cash and Due from Banks		 26 98 14 36 22 36 32 40
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 25 29 30 30 29 29 5.56 4.84
Other Assets		 956 896 864 949 1,052 1,044 993 873
Total Liabilities & Shareholders' Equity		 1,437 1,395 1,257 1,341 1,382 1,311 1,030 918
Total Liabilities		 983 959 878 944 931 977 982 987
Short-Term Debt		 12 86 55 86 64 25 17 19
Accrued Interest Payable		 150 161 137 130 141 123 126 85
Other Short-Term Payables		 55 52 43 66 28 37 33 27
Long-Term Debt		 497 410 413 416 446 560 582 651
Other Long-Term Liabilities		 269 249 231 246 251 232 224 206
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 49 50 51 52 54 55 56 58
Total Equity & Noncontrolling Interests		 405 386 328 345 397 279 -6.91 -127
Total Preferred & Common Equity		 228 226 203 212 242 192 68 2.13
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 228 226 203 212 242 192 68 2.13
Common Stock		 649 659 662 665 674 683 725 729
Retained Earnings		 -419 -429 -455 -449 -428 -482 -648 -718
Treasury Stock		 -2.42 -3.58 -3.98 -4.12 -4.97 -9.18 -9.28 -9.40
Accumulated Other Comprehensive Income / (Loss)		 -0.06 -0.13 -0.15 -0.14 -0.21 -0.10 -0.06 -0.05
Noncontrolling Interest		 177 160 125 133 155 87 -75 -129

Annual Metrics And Ratios for GoHealth

This table displays calculated financial ratios and metrics derived from GoHealth's official financial filings.

Metric 2018 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 321,180,070.00 320,708,380.00 329,214,542.00 22,371,118.00 - 28,714,000.00
DEI Adjusted Shares Outstanding		 0.00 21,412,005.00 21,380,559.00 21,947,636.00 22,371,118.00 - 28,714,000.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -4.54 -24.99 -17.15 -6.76 - -17.33
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 3,184.64% -43.50% -112.09% 8.90% -110.19%
EBITDA Growth		 0.00% 0.00% -12,362.99% 37.47% 84.12% 358.13% -480.15%
EBIT Growth		 0.00% 0.00% -448.52% 29.75% 59.77% 96.11% -8,426.61%
NOPAT Growth		 0.00% 0.00% -448.52% 29.75% 59.78% 96.11% -8,413.25%
Net Income Growth		 0.00% 0.00% -449.58% 29.54% 59.81% 95.16% -6,700.86%
EPS Growth		 0.00% 0.00% -449.58% 33.88% 59.42% 90.82% -2,956.06%
Operating Cash Flow Growth		 0.00% 0.00% -161.79% 120.37% 79.20% -119.80% -464.39%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 225.81% -80.01% -86.39% -1,674.27%
Invested Capital Growth		 0.00% 0.00% -11.04% -30.02% -13.30% -1.03% -26.56%
Revenue Q/Q Growth		 0.00% 0.00% 1,797.05% -35.35% -116.52% -21.44% -116.80%
EBITDA Q/Q Growth		 0.00% 0.00% -413.09% 51.18% 77.83% 136.07% -54.66%
EBIT Q/Q Growth		 0.00% 0.00% -1,818.46% 42.90% 49.44% 91.32% -31.81%
NOPAT Q/Q Growth		 0.00% 0.00% -1,297.62% 42.83% 49.57% 91.26% -32.19%
Net Income Q/Q Growth		 0.00% 0.00% -1,817.61% 42.79% 49.53% 89.17% -30.40%
EPS Q/Q Growth		 0.00% 0.00% -1,817.61% 35.47% 44.73% 77.55% -43.25%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -38.77% 148.85% 3,554.92% -161.58% -78.63%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 327.72% -82.38% -63.32% -597.89%
Invested Capital Q/Q Growth		 0.00% 0.00% -9.90% -20.83% 1.38% 7.41% 9.55%
Profitability Metrics		 - - - - - - -
EBITDA Margin		 0.00% 0.00% -41.81% -46.26% 0.00% 13.62% 0.00%
EBIT Margin		 0.00% 0.00% -52.60% -65.39% 0.00% -0.74% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -52.53% -65.50% 0.00% -0.91% 0.00%
Tax Burden Percent		 99.84% 100.04% 100.00% 100.20% 100.10% 144.87% 99.33%
Interest Burden Percent		 98.67% 99.63% 99.87% 99.97% 99.98% 85.83% 99.84%
Effective Tax Rate		 0.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -21.91% -19.24% 0.00% -0.42% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -50.30% -37.37% 0.00% -1.05% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -24.71% -31.48% 0.00% -1.18% 0.00%
Return on Equity (ROE)		 0.00% -8.60% -46.62% -50.72% -28.91% -1.60% -219.72%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -10.23% 16.08% 4.18% 0.62% -11.24%
Operating Return on Assets (OROA)		 0.00% 0.00% -25.61% -20.16% 0.00% -0.39% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -25.57% -20.19% 0.00% -0.49% 0.00%
Return on Common Equity (ROCE)		 0.00% -4.72% -14.92% -21.25% -13.80% -0.83% -135.65%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -25.55% -151.29% -140.05% -65.48% -3.03% -1,314.27%
Net Operating Profit after Tax (NOPAT)		 28 -68 -374 -263 -106 -4.12 -351
NOPAT Margin		 0.00% 0.00% -36.82% -45.77% 0.00% -0.52% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 7.07% 28.39% 18.13% 8.62% 0.62% 24.05%
SG&A Expenses to Revenue		 0.00% 0.00% 40.67% 44.14% 0.00% 34.59% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 152.60% 165.39% 0.00% 100.74% 0.00%
Earnings before Interest and Taxes (EBIT)		 29 -98 -535 -376 -151 -5.89 -502
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 35 3.47 -425 -266 -42 109 -414
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 11.53 3.44 0.85 1.29 1.27 1.63
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 1.89
Price to Revenue (P/Rev)		 0.00 0.00 1.20 0.40 0.00 0.38 0.00
Price to Earnings (P/E)		 29.50 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 3.14 1.48 0.95 0.98 1.02 0.99
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 2.35 1.86 0.00 1.24 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 1,635.75 0.00 0.00 0.00 9.09 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 17.57 8.73 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 4.87 21.67 165.53 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.29 0.80 0.90 1.15 1.11 -134.38
Long-Term Debt to Equity		 0.00 0.28 0.75 0.85 0.93 0.98 -119.71
Financial Leverage		 0.00 0.29 0.49 0.84 1.01 1.13 2.70
Leverage Ratio		 0.00 1.64 1.82 2.51 3.02 3.27 5.46
Compound Leverage Factor		 0.00 1.64 1.82 2.51 3.02 2.81 5.46
Debt to Total Capital		 0.00% 22.63% 44.53% 47.45% 53.39% 52.55% 100.75%
Short-Term Debt to Total Capital		 0.00% 0.71% 3.18% 2.61% 10.09% 6.19% 11.00%
Long-Term Debt to Total Capital		 0.00% 21.92% 41.34% 44.84% 43.30% 46.36% 89.75%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 56.33% 33.53% 28.68% 22.94% 22.42% -6.09%
Common Equity to Total Capital		 0.00% 21.04% 21.95% 23.87% 23.67% 25.03% 5.34%
Debt to EBITDA		 0.00 118.06 -1.68 -2.01 -12.35 4.66 -1.73
Net Debt to EBITDA		 0.00 76.45 -1.49 -1.95 -10.20 4.28 -1.65
Long-Term Debt to EBITDA		 0.00 114.34 -1.56 -1.90 -10.01 4.11 -1.54
Debt to NOPAT		 0.00 -6.00 -1.91 -2.03 -4.93 -123.21 -2.04
Net Debt to NOPAT		 0.00 -3.88 -1.69 -1.97 -4.07 -113.28 -1.94
Long-Term Debt to NOPAT		 0.00 -5.81 -1.78 -1.92 -4.00 -108.70 -1.82
Noncontrolling Interest Sharing Ratio		 0.00% 45.09% 67.99% 58.10% 52.25% 48.23% 38.26%
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -175 220 44 5.98 -94
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -5.22 3.85 0.63 0.08 -1.08
Operating Cash Flow to Interest Expense		 24.30 -3.46 -8.92 1.07 1.57 -0.30 -1.40
Operating Cash Flow Less CapEx to Interest Expense		 24.30 -3.46 -8.92 1.07 1.57 -0.30 -1.40
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.49 0.31 0.00 0.54 0.00
Fixed Asset Turnover		 0.00 0.00 48.86 23.19 0.00 28.49 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 1,808 1,609 1,126 976 966 709
Invested Capital Turnover		 0.00 0.00 0.60 0.42 0.00 0.82 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 -200 -483 -150 -10 -257
Enterprise Value (EV)		 0.00 5,671 2,387 1,070 953 990 700
Market Capitalization		 830 4,387 1,215 229 298 307 62
Book Value per Share		 $0.00 $1.18 $1.10 $0.82 $10.33 $10.56 $1.32
Tangible Book Value per Share		 $0.00 ($2.16) ($0.75) ($0.70) ($7.40) ($2.65) $1.14
Total Capital		 0.00 1,808 1,609 1,126 976 966 709
Total Debt		 0.00 409 716 534 521 508 715
Total Long-Term Debt		 0.00 396 665 505 423 448 637
Net Debt		 0.00 265 632 518 430 467 682
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 0.38 29 160 113 45 3.20 147
Net Nonoperating Obligations (NNO)		 0.00 409 716 534 521 508 715
Total Depreciation and Amortization (D&A)		 6.16 101 110 110 109 115 88
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.30) ($26.85) ($17.72) ($7.19) ($0.66) ($20.17)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 21.41M 7.07M 8.45M 9.29M 9.98M 12.94M
Adjusted Diluted Earnings per Share		 $0.00 ($3.30) ($26.85) ($17.72) ($7.19) ($0.66) ($20.17)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 21.41M 7.07M 8.45M 9.29M 9.98M 12.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.30) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 5.61M 21.42M 22.04M 22.48M 23.01M 28.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -197 -669 -103 -237 -611 -4.12 -422
Normalized NOPAT Margin		 0.00% 0.00% -10.14% -41.20% 0.00% -0.52% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -52.53% -65.37% 0.00% -0.63% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 127.41 -2.96 -15.96 -6.58 -2.18 -0.08 -5.75
NOPAT to Interest Expense		 127.20 -2.07 -11.18 -4.61 -1.52 -0.06 -4.02
EBIT Less CapEx to Interest Expense		 127.41 -2.96 -15.96 -6.58 -2.18 -0.08 -5.75
NOPAT Less CapEx to Interest Expense		 127.20 -2.07 -11.18 -4.61 -1.52 -0.06 -4.02
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.36% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.36% 0.00% 0.00%

Quarterly Metrics And Ratios for GoHealth

This table displays calculated financial ratios and metrics derived from GoHealth's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 22,329,782.00 22,371,118.00 22,481,576.00 22,728,197.00 22,838,868.00 - 23,009,065.00 23,738,413.00 28,609,238.00 28,714,000.00 28,846,134.00
DEI Adjusted Shares Outstanding		 22,329,782.00 22,371,118.00 22,481,576.00 22,728,197.00 22,838,868.00 - 23,009,065.00 23,738,413.00 28,609,238.00 28,714,000.00 28,846,134.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.52 -0.10 -0.95 -2.61 0.67 - -0.43 -4.89 -10.97 -2.02 -2.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.45% -151.87% 1,092.53% 608.39% 33.73% -45.20% 22.29% -119.31% -114.96% -156.84% -109.21%
EBITDA Growth		 37.84% 120.26% 22.78% 31.86% 257.85% 251.65% 229.23% -203.37% -731.71% -166.80% -442.09%
EBIT Growth		 25.72% 98.21% 2.90% 16.47% 128.10% 2,299.85% 57.76% -98.16% -2,114.32% -204.61% -606.30%
NOPAT Growth		 25.72% 98.73% 2.67% 16.49% 140.17% 4,341.34% 57.76% -98.18% -1,509.33% -175.92% -606.30%
Net Income Growth		 24.71% 98.48% 5.31% 15.54% 127.34% 2,627.25% 54.16% -95.55% -2,142.94% -200.15% -575.82%
EPS Growth		 23.46% 98.21% 7.14% 17.43% 117.62% 2,069.23% 50.00% -88.89% -2,665.22% -207.42% -353.85%
Operating Cash Flow Growth		 -93.20% 273.91% -38.90% -436.03% -288.11% -79.52% -199.14% -3.62% -167.04% -367.56% 156.32%
Free Cash Flow Firm Growth		 35.08% -60.70% -65.44% -64.80% -81.19% -54.88% -123.57% -214.57% -59.81% 218.79% 972.18%
Invested Capital Growth		 -32.29% -13.30% -15.32% -17.09% -6.59% -1.03% 3.18% 8.44% -28.00% -26.56% -37.52%
Revenue Q/Q Growth		 864.77% -226.75% -73.67% -47.64% 101.16% 78.36% -53.50% -108.27% -55.90% -848.75% 92.47%
EBITDA Q/Q Growth		 33.81% 187.43% -77.86% -631.82% 253.34% 94.78% -79.27% -590.05% -219.29% 79.40% -6.14%
EBIT Q/Q Growth		 20.97% 95.15% -716.91% -167.05% 126.58% 279.35% -115.68% -1,152.89% -170.21% 80.30% -5.90%
NOPAT Q/Q Growth		 21.00% 96.55% -1,047.94% -167.05% 138.00% 264.08% -111.43% -1,153.01% -170.24% 80.39% -6.36%
Net Income Q/Q Growth		 19.97% 95.92% -830.51% -177.87% 125.91% 277.29% -116.88% -1,085.25% -170.64% 81.50% -13.91%
EPS Q/Q Growth		 20.18% 95.02% -700.00% -159.62% 117.04% 456.52% -120.31% -880.77% -131.37% 76.69% 14.18%
Operating Cash Flow Q/Q Growth		 -40.15% 996.94% -82.45% -391.69% 66.50% 219.44% -184.94% -204.85% 13.66% -19.67% 117.88%
Free Cash Flow Firm Q/Q Growth		 10.82% -64.69% 3.24% -12.85% -40.79% -15.30% -153.93% -323.59% 120.77% 571.80% 47.55%
Invested Capital Q/Q Growth		 -5.76% 1.38% -4.50% -9.13% 6.17% 7.41% -0.44% -4.49% -29.51% 9.55% -15.29%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 -21.62% 0.00% 3.30% -33.48% 25.52% 25.15% 8.87% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -42.06% 0.00% -13.11% -66.88% 8.84% 16.96% -4.53% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -42.57% 0.00% -12.73% -67.58% 8.70% 16.61% -4.77% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.81% 119.79% 99.67% 99.93% 100.07% 96.04% 112.69% 99.70% 99.85% 94.16% 101.09%
Interest Burden Percent		 101.39% 71.16% 97.43% 101.10% 98.40% 101.97% 93.53% 100.01% 100.02% 99.57% 99.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% -0.07% 3.96% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -10.38% 0.00% -8.30% -51.32% 10.15% 13.42% -3.05% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -13.29% 0.00% -9.46% -55.04% 10.10% 13.64% -3.70% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -13.31% 0.00% -9.61% -60.67% 12.00% 15.36% -4.20% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.69% -28.91% -17.91% -111.99% 22.15% 28.79% -7.25% 0.00% 0.00% -219.72% -289.94%
Cash Return on Invested Capital (CROIC)		 20.92% 4.18% 6.26% 8.27% 1.75% 0.62% -2.73% -12.01% -1.74% -11.24% -3.79%
Operating Return on Assets (OROA)		 -10.29% 0.00% -8.20% -50.02% 6.80% 9.08% -2.97% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -10.41% 0.00% -7.97% -50.53% 6.69% 8.90% -3.13% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -10.99% -13.80% -8.69% -57.02% 11.45% 14.90% -3.82% 0.00% 0.00% -135.65% -184.91%
Return on Equity Simple (ROE_SIMPLE)		 -131.49% 0.00% -66.44% -68.64% -31.88% 0.00% 1.76% -27.34% -559.95% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -39 -1.34 -15 -41 16 57 -6.50 -81 -220 -43 -46
NOPAT Margin		 -29.45% 0.00% -9.18% -46.82% 8.84% 16.29% -3.17% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 2.90% 0.18% 1.16% 3.72% 0.05% -0.22% 0.65% 6.56% 17.05% 2.44% 3.43%
SG&A Expenses to Revenue		 38.68% 0.00% 37.77% 53.06% 31.19% 32.03% 37.29% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 142.06% 0.00% 113.11% 166.88% 91.16% 83.04% 104.53% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -56 -2.69 -22 -59 16 59 -9.29 -116 -314 -62 -66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 25 5.53 -29 45 88 18 -89 -285 -59 -62
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.42 1.29 1.05 1.09 1.01 1.27 1.17 0.69 2.02 1.63 20.44
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.02 1.89 20.44
Price to Revenue (P/Rev)		 0.77 0.00 0.26 0.22 0.20 0.38 0.31 0.18 0.26 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 150.17 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.67% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.07 0.98 0.91 1.00 0.96 1.02 1.02 0.90 1.06 0.99 1.00
Enterprise Value to Revenue (EV/Rev)		 2.45 0.00 0.92 0.83 0.81 1.24 1.08 1.12 1.29 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 18.77 9.09 8.06 13.30 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 143.92 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 260.66 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 8.73 8.35 15.82 24.68 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 4.14 21.67 13.28 11.01 53.11 165.53 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.12 1.15 1.14 1.24 1.26 1.11 1.13 1.75 12.22 -134.38 -9.74
Long-Term Debt to Equity		 1.09 0.93 0.94 1.09 1.05 0.98 0.99 1.68 11.88 -119.71 -9.46
Financial Leverage		 1.00 1.01 1.02 1.10 1.19 1.13 1.14 1.48 2.47 2.70 3.09
Leverage Ratio		 2.89 3.02 2.91 3.08 3.26 3.27 3.13 3.60 5.31 5.46 6.02
Compound Leverage Factor		 2.93 2.15 2.84 3.12 3.21 3.34 2.93 3.60 5.32 5.44 6.00
Debt to Total Capital		 52.86% 53.39% 53.25% 55.27% 55.83% 52.55% 53.11% 63.65% 92.44% 100.75% 111.45%
Short-Term Debt to Total Capital		 1.25% 10.09% 9.23% 6.48% 9.54% 6.19% 6.70% 2.69% 2.59% 11.00% 3.17%
Long-Term Debt to Total Capital		 51.61% 43.30% 44.01% 48.79% 46.29% 46.36% 46.41% 60.96% 89.85% 89.75% 108.28%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 23.47% 22.94% 22.52% 20.80% 20.60% 22.42% 21.77% 15.48% -2.96% -6.09% -11.80%
Common Equity to Total Capital		 23.67% 23.67% 24.23% 23.93% 23.57% 25.03% 25.12% 20.88% 10.53% 5.34% 0.35%
Debt to EBITDA		 -2.67 -12.35 -12.05 -17.06 10.88 4.66 4.20 9.45 -2.24 -1.73 -1.35
Net Debt to EBITDA		 -2.54 -10.20 -9.68 -16.55 10.11 4.28 4.02 8.88 -2.12 -1.65 -1.27
Long-Term Debt to EBITDA		 -2.61 -10.01 -9.96 -15.06 9.02 4.11 3.67 9.05 -2.17 -1.54 -1.32
Debt to NOPAT		 -2.43 -4.93 -4.73 -4.81 -10.65 -123.21 135.82 -16.94 -2.26 -2.04 -1.72
Net Debt to NOPAT		 -2.30 -4.07 -3.80 -4.67 -9.90 -113.28 129.93 -15.91 -2.14 -1.94 -1.61
Long-Term Debt to NOPAT		 -2.37 -4.00 -3.91 -4.25 -8.83 -108.70 118.69 -16.23 -2.19 -1.82 -1.67
Noncontrolling Interest Sharing Ratio		 53.60% 52.25% 51.47% 49.08% 48.31% 48.23% 47.28% 0.00% 0.00% 38.26% 36.22%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 420 148 153 134 79 67 -36 -153 32 213 315
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 4.20 8.53 7.38 4.14 1.82 -2.26 -9.03 1.28 7.20 10.23
Operating Cash Flow to Interest Expense		 0.00 2.02 0.70 -2.02 -0.64 0.40 -0.78 -2.23 -1.32 -1.32 0.23
Operating Cash Flow Less CapEx to Interest Expense		 0.00 2.02 0.70 -2.02 -0.64 0.40 -0.78 -2.23 -1.32 -1.32 0.23
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.24 0.00 0.63 0.75 0.77 0.54 0.66 0.57 0.45 0.00 0.00
Fixed Asset Turnover		 16.09 0.00 34.33 38.14 38.33 28.49 31.40 24.71 29.45 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 963 976 932 847 899 966 962 919 648 709 601
Invested Capital Turnover		 0.35 0.00 0.90 1.10 1.15 0.82 0.96 0.83 0.68 0.00 0.00
Increase / (Decrease) in Invested Capital		 -459 -150 -169 -175 -63 -10 30 72 -252 -257 -361
Enterprise Value (EV)		 1,032 953 845 851 866 990 980 823 685 700 603
Market Capitalization		 324 298 236 221 214 307 282 132 138 62 44
Book Value per Share		 $10.21 $10.33 $10.05 $8.92 $9.28 $10.56 $10.50 $8.08 $2.38 $1.32 $0.07
Tangible Book Value per Share		 ($9.05) ($7.40) ($6.55) ($6.46) ($4.99) ($2.65) ($1.62) ($0.45) $2.38 $1.14 $0.07
Total Capital		 963 976 932 847 899 966 962 919 648 709 601
Total Debt		 509 521 496 468 502 508 511 585 599 715 670
Total Long-Term Debt		 497 423 410 413 416 448 446 560 582 637 651
Net Debt		 483 430 399 454 467 467 489 549 567 682 630
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 17 0.95 5.96 18 0.25 -1.12 3.29 35 94 15 20
Net Nonoperating Obligations (NNO)		 509 521 496 468 502 508 511 585 599 715 670
Total Depreciation and Amortization (D&A)		 27 28 28 29 29 29 27 27 30 3.30 3.35
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.61) ($0.13) ($1.04) ($2.70) $0.58 $2.56 ($0.52) ($5.10) ($11.80) ($2.75) ($2.36)
Adjusted Weighted Average Basic Shares Outstanding		 9.49M 9.29M 9.72M 9.97M 10.08M 9.98M 10.37M 10.83M 14.14M 12.94M 16.20M
Adjusted Diluted Earnings per Share		 ($2.61) ($0.13) ($1.04) ($2.70) $0.46 $2.56 ($0.52) ($5.10) ($11.80) ($2.75) ($2.36)
Adjusted Weighted Average Diluted Shares Outstanding		 9.49M 9.29M 9.72M 9.97M 14.58M 9.98M 10.37M 10.83M 14.14M 12.94M 16.20M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.13) $0.00 $0.00 $0.00 $2.56 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 22.37M 22.48M 22.73M 22.84M 22.91M 23.01M 23.74M 28.61M 28.71M 28.85M 29.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -1.34 -15 -41 11 57 -6.00 -110 -100 -43 -46
Normalized NOPAT Margin		 -29.45% 0.00% -9.18% -46.82% 6.19% 16.29% -2.93% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -42.65% 0.00% -12.77% -67.62% 8.70% 17.30% -4.24% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -0.08 -1.22 -3.24 0.82 1.61 -0.58 -6.87 -12.69 -2.09 -2.13
NOPAT to Interest Expense		 0.00 -0.04 -0.86 -2.27 0.82 1.54 -0.41 -4.81 -8.89 -1.46 -1.49
EBIT Less CapEx to Interest Expense		 0.00 -0.08 -1.22 -3.24 0.82 1.61 -0.58 -6.87 -12.69 -2.09 -2.13
NOPAT Less CapEx to Interest Expense		 0.00 -0.04 -0.86 -2.27 0.82 1.54 -0.41 -4.81 -8.89 -1.46 -1.49
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -0.89% -2.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.89% -2.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

GoHealth Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GoHealth's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

GoHealth's net income appears to be on an upward trend, with a most recent value of -$497.76 million in 2025, falling from $28.11 million in 2018. The previous period was -$7.32 million in 2024. Find out what analysts predict for GoHealth in the coming months.

Over the last 6 years, GoHealth's total revenue changed from -$224 thousand in 2018 to -$88.98 million in 2025, a change of 39,621.0%.

GoHealth's total liabilities were at $992.70 million at the end of 2025, a 3.6% decrease from 2024, and a 33.8% increase since 2019.

In the past 6 years, GoHealth's cash and equivalents has ranged from $12.28 million in 2019 to $144.23 million in 2020, and is currently $32.90 million as of their latest financial filing in 2025.

Over the last 6 years, GoHealth's book value per share changed from 0.00 in 2018 to 1.32 in 2025, a change of 131.9%.


Related Companies

Financial statements for NASDAQ:GOCO last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Move your money (NOT into the next AI IPO)
While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...
Stansberry Research | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel